CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second- or third-line setting in NSCLC. However, clinical surrogate markers of EGFR-TKI activity in NSCLC patients remain to be identified and we studied the prognostic value of...

Descripción completa

Detalles Bibliográficos
Autores principales: Barlési, F, Tchouhadjian, C, Doddoli, C, Torre, J-P, Astoul, P, Kleisbauer, J-P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361739/
https://www.ncbi.nlm.nih.gov/pubmed/15597098
http://dx.doi.org/10.1038/sj.bjc.6602296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361739/
https://www.ncbi.nlm.nih.gov/pubmed/15597098
http://dx.doi.org/10.1038/sj.bjc.6602296

Ejemplares similares